2. Autophagy Apoptosis Immunology/Inflammation
  3. Autophagy Apoptosis Interleukin Related
  4. Vitamin K2

Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma.

For research use only. We do not sell to patients.

Vitamin K2

Vitamin K2 Chemical Structure

CAS No. : 11032-49-8

Size Price Stock Quantity
1 mg Get quote 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks
5 mg Get quote 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks
10 mg Get quote 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks
25 mg Get quote 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks
50 mg Get quote 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks
100 mg Get quote 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks
200 mg   Get quote  
500 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Vitamin K2:

Vitamin K2 Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma[1][2][3][4].

IC50 & Target[3]

IL-6

 

IL-1β

 

In Vitro

Vitamin K2 (10-9-10-5 M; 3 days) dose-dependently suppresses the proliferation of human osteosarcoma HOS TE85 cells (maximal effect at 10-7 M, reducing cell number to 56% of control) and murine osteoblastic MC3T3-E1 cells (maximal effect at 10-6 M, reducing cell number to 84% of control) after 3 days of incubation, and this suppressive effect is reversed by co-incubation with warfarin[1].
Vitamin K2 (6-14 μM; 96 h) inhibits the growth of HL-60neo human leukemia cells with an IC50 of 6 μM and HL-60bcl-2 human leukemia cells with an IC50 of 14 μM after 96-hour exposure[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vitamin K2 Related Antibodies

Cell Autophagy Assay[4]

Cell Line: HL-60neo, HL-60bcl-2 human leukemia cell lines
Concentration: 5 μM, 10 μM, 20 μM
Incubation Time: 72 h
Result: Increased the percentage of cells with bright red fluorescence (AVOs) from 4.8% to 46.8% in HL-60neo cells and from 4.7% to 47.3% in HL-60bcl-2 cells at 10 μM.
In Vivo

Vitamin K2 (0.1-0.4 mg/kg; p.o.; daily; 8 weeks) exerts significant protective effects against high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) in mice, including reducing body weight, abdominal circumference and body fat[2].
Vitamin K2 (15-60 mg/kg; p.o.; 14 days) alleviates dextran sulfate sodium (DSS)-induced ulcerative colitis in male C57BL/6J mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (male, 7 weeks old, DSS-induced ulcerative colitis)[3]
Dosage: 15 mg/kg·bw; 30 mg/kg·bw; 60 mg/kg·bw
Administration: i.g.; daily; 14 days
Result: Restored body weight, reduced Disease Activity Index (DAI) score, increased colon length.
Reduced spleen weigh, improved colonic histopathology, restored goblet cell numbers.
Reduced colonic IL-1β and TNF-α levels, increased colonic IL-10 levels, elevated colonic ZO-1, occludin, and muc2 protein expression, reversed DSS-induced increases in Deferribacteres abundance.
Increased fecal acetic acid, propionic acid, and total SCFA levels at 15 mg/kg·bw.
Clinical Trial
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

[Vitamin K2]
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL; Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL; Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Vitamin K2 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vitamin K211032-49-8Vitamin K 2Vitamin K-2AutophagyApoptosisInterleukin RelatedILosteoblastic cellscolitis miceosteosarcoma cellsC57BL/6J micenon-alcoholic fatty liver disease miceHL-60neo human leukemia cellsγ-carboxyglutamic acidC57BL/6 male miceHL-60bcl-2 human leukemia cellsγ-carboxylaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vitamin K2
Cat. No.:
HY-109569
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (254 KB) Français - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Español - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.